Led · Series B · Jul 2026

Materna Medical develops technologies addressing unmet needs in women's pelvic health, with a mission to transform the standard of care in OBGYN. Its first product, Milli, is a vaginal dilator originally launched as a wellness trainer in 2019 and cleared by the FDA in 2023 for over-the-counter sale. Milli outcomes have been studied in a post-market prospective virtual study called POMPOM. Materna's second product, Ellora, is an investigational device intended to reduce pelvic floor muscle injury during vaginal delivery and is being evaluated in the randomized EASE trial across 20 U.S. hospitals. The company recently raised $5 million in a B3 financing to support completion of the EASE trial readout, expand Milli channel access, and prepare Ellora's commercialization and manufacturing. Materna is headquartered in Mountain View, California.

Participated · Series A · Jun 2026

Tombot develops lifelike, fully autonomous robotic companion animals designed to provide comfort and emotional support for older adults and individuals with dementia, anxiety, autism, PTSD, or loneliness. Its flagship product, Jennie, mimics the movements and responses of an 8–10 week-old puppy and has attracted more than 23,000 pre-order and waitlist customers. Jennie first emerged in the marketplace in early 2024 and has generated interest from consumers, healthcare providers, senior living organizations, and caregiving communities. The company is based in Santa Clarita, California, and is preparing for a planned Fall 2026 customer launch. Tombot recently raised $7 million in a Series A3 round to scale manufacturing, expand operations, accelerate commercialization, and expand its companion robotics product line.

Participated · Seed · Jun 2026

ChemT Biotechnology builds an AI-driven Virtual Cell platform called CelMo, trained on billions to trillions of proprietary sequencing reads and validated in the lab to simulate how cells respond to manufacturing conditions, genetic changes, and stresses. Using CelMo, ChemT identifies target cell pathways, designs small molecules to modulate cell behavior, and supports cell engineering to improve manufacturing performance. The company reports CelMo has delivered a 50% increase in antibody output and a 40% reduction in production timelines in CHO cells. Its flagship small-molecule product Chemplify for T-cell manufacturing has demonstrated 50% faster development, 3× scalability, 60% lower costs, and 10× higher cell expansion yield. ChemT says it has established commercial partnerships with more than 40 pharmaceutical, biotech, and CDMO customers globally. The company plans to expand CelMo beyond CHO and T cells into stem cells, NK cells, and HEK cells while advancing products toward GMP and regulatory readiness.

Participated · Seed · Jun 2026

Lium (formerly Astromind) builds an "agentic harness" platform that creates custom AI agents to restructure raw scientific and industrial datasets—such as satellite imagery, seismic surveys, electromagnetic spectrum data, and sparse X‑ray measurements—so large language models can reason over them. The company reports early traction with paying customers, including work with astrophysicists on exoplanet X‑ray analysis, processing terabytes of satellite and weather data for the North Carolina Institute for Climate Studies, and automating electromagnetic spectrum analysis for industrial partner nexGEN Inc. Lium says its agents improve over time as more queries hit a dataset, aiming to reduce LLM hallucinations when handling complex numerical inputs. The startup raised a $5.5M seed led by SJF Ventures to launch and scale this platform. No revenue figures were disclosed in the article.

Participated · Series A · Jun 2026

Founded in 2022 by former NHS doctor Dr Sonia Szamocki, 01Health develops a platform that combines specialist oversight, clinical protocols, patient communication tools, operational workflows and AI-powered patient acquisition to enable specialist services to be delivered through local clinics. The technology has been applied within the company’s own services, including orthodontics platform 32Co and dental sleep medicine provider Aerox Health, and 32Co has helped build a nationwide network of providers offering specialist orthodontic treatment in the UK. While initially focused on dentistry, 01Health has developed the platform to support additional clinical specialties and is running trials beyond dental care. With the new $15M Series A, the company plans to commercialise the platform as a standalone licensed offering for practices, clinic groups and dental service organisations and to expand into the US market.